Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution
ConclusionThe incidence of FN induced by adjuvant/neoadjuvant chemotherapy in ESBC is higher in routine clinical practice than in clinical trials. AI or inflammatory diseases were significant independent risk factors for FN. Primary prophylaxis in patients at risk (elderly, comorbid patients), especially treated with the FEC regimen, is the keystone of management of this adverse effect. Prevention and management of FN to ensure the patient ’s safety and quality of life are a major issue for both medical oncologists and supportive care physicians.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Autoimmune Disease | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Cipro | Ciprofloxacin | Clinical Trials | Docetaxel | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Taxotere | Toxicology